Angiotensin-I-Converting Enzyme and Prolyl Endopeptidase Inhibitory Peptides from Marine Processing By-Products
Total Page:16
File Type:pdf, Size:1020Kb
Load more
Recommended publications
-
(Apis Mellifera) ELISABETH P
J. Insect Ph.vsiol. Vol. 42, No. 9, pp. 823-828, 1996 Pergamon Copyright 0 1996 Elsevier Science Ltd Printed in Great Britain. All rights reserved PII: SOO22-1910(96)00045-5 0022-1910196 $15.00 + 0.00 Effects of Two Proteinase Inhibitors on the Digestive Enzymes and Survival of Honey Bees (Apis mellifera) ELISABETH P. J. BURGESS,*1 LOUISE A. MALONE,* JOHN T. CHRlSTELLERt Received I1 December 1995; revised und accepted 1 March 1996 Two endopeptidase inhibitors, BPTI (bovine pancreatic trypsin inhibitor) and SBTI (Kunitz soybean trypsin inhibitor), were found to significantly reduce the longevity of adult honey bees (&is mellifera L.) fed the inhibitors ad lib in sugar syrup at l.O%, 0.5% or O.l%, but not at 0.01% or 0.001% (w:v). Bees were taken from frames at emergence, kept in cages at 33”C, and provided with a pollen/protein diet, water and syrup. In vivo activity levels of three midgut endopeptidases (trypsin, chymotrypsin and elastase) and the exopeptidase leucine aminopeptidase (LAP) were determined in bees fed either BPTI or SBTI at l.O%, 0.3% or 0.1% (w:v) at two time points: the 8th day after emergence and when 75% of bees had died. LAP activity levels increased significantly in bees fed with either inhibitor at all concen- trations. At day 8, bees fed BPTI at all concentrations had significantly reduced levels of trypsin, chymotrypsin and elastase. At the time of 75% mortality, bees fed BPTI at each concentration had reduced trypsin levels, but only those fed the inhibitor at the highest dose level had reduced chymotrypsin or elastase activity. -
Treatment Protocol Copyright © 2018 Kostoff Et Al
Prevention and reversal of Alzheimer's disease: treatment protocol Copyright © 2018 Kostoff et al PREVENTION AND REVERSAL OF ALZHEIMER'S DISEASE: TREATMENT PROTOCOL by Ronald N. Kostoffa, Alan L. Porterb, Henry. A. Buchtelc (a) Research Affiliate, School of Public Policy, Georgia Institute of Technology, USA (b) Professor Emeritus, School of Public Policy, Georgia Institute of Technology, USA (c) Associate Professor, Department of Psychiatry, University of Michigan, USA KEYWORDS Alzheimer's Disease; Dementia; Text Mining; Literature-Based Discovery; Information Technology; Treatments Prevention and reversal of Alzheimer's disease: treatment protocol Copyright © 2018 Kostoff et al CITATION TO MONOGRAPH Kostoff RN, Porter AL, Buchtel HA. Prevention and reversal of Alzheimer's disease: treatment protocol. Georgia Institute of Technology. 2018. PDF. https://smartech.gatech.edu/handle/1853/59311 COPYRIGHT AND CREATIVE COMMONS LICENSE COPYRIGHT Copyright © 2018 by Ronald N. Kostoff, Alan L. Porter, Henry A. Buchtel Printed in the United States of America; First Printing, 2018 CREATIVE COMMONS LICENSE This work can be copied and redistributed in any medium or format provided that credit is given to the original author. For more details on the CC BY license, see: http://creativecommons.org/licenses/by/4.0/ This work is licensed under a Creative Commons Attribution 4.0 International License<http://creativecommons.org/licenses/by/4.0/>. DISCLAIMERS The views in this monograph are solely those of the authors, and do not represent the views of the Georgia Institute of Technology or the University of Michigan. This monograph is not intended as a substitute for the medical advice of physicians. The reader should regularly consult a physician in matters relating to his/her health and particularly with respect to any symptoms that may require diagnosis or medical attention. -
Development of Swiss Biotechnology Beyond the Biopharmaceutical Sector in Memoriam Prof
BUILDING BRIDGES BETWEEN BIOTECHNOLOGY AND CHEMISTRY – IN MEMORIAM ORESTE GHISALBA CHIMIA 2020, 74, No. 5 345 doi:10.2533/chimia.2020.345 Chimia 74 (2020) 345–359 © H.P. Meyer and O. Werbitzky Development of Swiss Biotechnology Beyond the Biopharmaceutical Sector In memoriam Prof. Dr. Oreste Ghisalba (1946–2018) Hans-Peter Meyera* and Oleg Werbitzkyb Abstract: Although diverse, the potential business opportunities for biotechnology outside the biopharmaceutical market are very large. White biotechnology can offer sustainable operations and products, while investments tend to be lower than those in red biotechnology. But a number of bottlenecks and roadblocks in Switzerland must be removed to realise the full potential of white biotechnology. This was also the point of view of Oreste Ghisalba, who wanted to be part of a new initiative to facilitate the creation of additional business, new pro- cesses and new products. This initiative requires the identification and the use of synergies and a much better cooperation between academia and industry through targeted networking. Unfortunately, we must carry on with this task without Oreste, whom we will miss for his deep knowledge and friendship. Keywords: Bio-based · Fine chemicals · Industrial biotechnology · Swiss economy · White biotechnology Hans-Peter Meyer holds a PhD in micro- venture partners and Managing Director of NC Health Sciences biology from the University of Fribourg since 2015. (Switzerland). He spent three years post- graduate and postdoc studies at the STFI 1. A Short History of the Swiss Biotechnology Industry in Stockholm (Sweden), the University The Swiss pharmaceutical and chemical industries have been of Pennsylvania and Lehigh University in responsible for almost half of the country’s exports for many years the USA. -
A CB1 Receptor Antagonist As a Direct Interactional Partner for Μ- and Δ-Opioid Receptor
Rimonabant: a CB1 receptor antagonist as a direct interactional partner for μ- and δ-opioid receptor Ph.D. thesis Ferenc Zádor Supervisor: Dr. Sándor Benyhe Institute of Biochemistry Biological Research Center of the Hungarian Academy of Sciences Szeged, Hungary 2014 TABLE OF CONTENTS LIST OF PUBLICATIONS ...................................................................................................... i LIST OF ABBREVIATIONS .................................................................................................. ii 1 REVIEW OF THE LITERATURE ................................................................................. 1 1.1 G-protein coupled receptors (GPCR) .............................................................................. 1 1.1.1 About GPCRs in general ................................................................................................................ 1 1.1.2 The structure of GPCRs ................................................................................................................. 3 1.1.3 The spectrum of GPCR ligand efficacy and constitutive activity of GPCRs ................................. 3 1.1.4 GPCR signaling: the G-protein activation/deactivation cycle ....................................................... 4 1.1.5 The complexity of GPCR signaling ............................................................................................... 6 1.2 Opioids and cannabinoids and their endogenous systems ............................................. 7 1.2.1 Opium poppy and the -
Combined Neprilysin and Renin–Angiotensin System Inhibition in Heart Failure with Reduced Ejection Fraction: a Meta-Analysis
European Journal of Heart Failure (2016) doi:10.1002/ejhf.603 Combined neprilysin and renin–angiotensin system inhibition in heart failure with reduced ejection fraction: a meta-analysis Scott D. Solomon1*, Brian Claggett1, John J.V. McMurray2, Adrian F. Hernandez3, and Gregg C. Fonarow4 1Cardiovascular Division, Brigham and Women’s Hospital, Harvard Medical School, Boston, MA, USA; 2University of Glasgow, Glasgow, UK; 3Duke University, Durham, NC, USA; and 4Ronald Reagan-UCLA Medical Center, Los Angeles, CA, USA Received 1 March 2016; revised 25 May 2016; accepted 3 June 2016 Aims The combined neprilysin/renin–angiotensin system (RAS) inhibitor sacubitril/valsartan reduced cardiovascular death or heart failure hospitalization, cardiovascular death, and all-cause mortality in a large outcomes trial. While sacubitril/valsartan is the only currently available drug in its class, there are two prior clinical trials in heart failure with omapatrilat, another combined neprilysin/RAS inhibitor. Using all available evidence can inform clinicians and policy-makers. ..................................................................................................................................................................... Methods We performed a meta-analysis using data from three trials in heart failure with reduced EF that compared combined and results neprilysin/RAS inhibition with RAS inhibition alone and reported clinical outcomes: IMPRESS (n = 573), OVERTURE (n = 5770), and PARADIGM-HF (n = 8399). We assessed the pooled hazard ratio (HR) for all-cause death or heart failure hospitalization, and for all-cause mortality in random-effects models, comparing combined neprilysin/RAS inhibition with ACE inhibition alone. The composite outcome of death or heart failure hospitalization was reduced numerically in patients receiving combined neprilysin/RAS inhibition in all three trials, with a pooled HR of 0.86, 95% confidence interval (CI) 0.76–0.97, P = 0.013. -
Metabolic Actions of Natriuretic Peptides and Therapeutic Potential in the Metabolic Syndrome
Pharmacology & Therapeutics 144 (2014) 12–27 Contents lists available at ScienceDirect Pharmacology & Therapeutics journal homepage: www.elsevier.com/locate/pharmthera Associate editor: G. Eisenhofer Metabolic actions of natriuretic peptides and therapeutic potential in the metabolic syndrome Nina Schlueter a,AnitadeSterkea, Diana M. Willmes a, Joachim Spranger a, Jens Jordan b,AndreasL.Birkenfelda,⁎ a Department of Endocrinology, Diabetes and Nutrition, Center for Cardiovascular Research, Charité, University School of Medicine, Berlin, Germany b Institute of Clinical Pharmacology, Hannover Medical School, Hannover, Germany article info abstract Available online 27 April 2014 Natriuretic peptides (NPs) are a group of peptide-hormones mainly secreted from the heart, signaling via c-GMP coupled receptors. NP are well known for their renal and cardiovascular actions, reducing arterial blood pressure Keywords: as well as sodium reabsorption. Novel physiological functions have been discovered in recent years, including Natriuretic peptides activation of lipolysis, lipid oxidation, and mitochondrial respiration. Together, these responses promote white ANP adipose tissue browning, increase muscular oxidative capacity, particularly during physical exercise, and protect BNP against diet-induced obesity and insulin resistance. Exaggerated NP release is a common finding in congestive Insulin resistance heart failure. In contrast, NP deficiency is observed in obesity and in type-2 diabetes, pointing to an involvement Diabetes fi Obesity of NP in the pathophysiology of metabolic disease. Based upon these ndings, the NP system holds the potential to be amenable to therapeutical intervention against pandemic diseases such as obesity, insulin resistance, and arterial hypertension. Various therapeutic approaches are currently under development. This paper reviews the current knowledge on the metabolic effects of the NP system and discusses potential therapeutic applications. -
ACE2–Angiotensin-(1–7)–Mas Axis and Oxidative Stress in Cardiovascular Disease
Hypertension Research (2011) 34, 154–160 & 2011 The Japanese Society of Hypertension All rights reserved 0916-9636/11 $32.00 www.nature.com/hr REVIEW SERIES ACE2–angiotensin-(1–7)–Mas axis and oxidative stress in cardiovascular disease Luiza A Rabelo1,2, Natalia Alenina1 and Michael Bader1 The renin–angiotensin–aldosterone system (RAAS) is a pivotal regulator of physiological homeostasis and diseases of the cardiovascular system. Recently, new factors have been discovered, such as angiotensin-converting enzyme 2 (ACE2), angiotensin-(1–7) and Mas. This newly defined ACE2–angiotensin-(1–7)–Mas axis was shown to have a critical role in the vasculature and in the heart, exerting mainly protective effects. One important mechanism of the classic and the new RAAS regulate vascular function is through the regulation of redox signaling. Angiotensin II is a classic prooxidant peptide that increases superoxide production through the activation of NAD(P)H oxidases. This review summarizes the current knowledge about the ACE2–angiotensin-(1–7)–Mas axis and redox signaling in the context of cardiovascular regulation and disease. By interacting with its receptor Mas, angiotensin-(1–7) induces the release of nitric oxide from endothelial cells and thereby counteracts the effects of angiotensin II. ACE2 converts angiotensin II to angiotensin-(1–7) and, thus, is a pivotal regulator of the local effects of the RAAS on the vessel wall. Taken together, the ACE2–angiotensin-(1–7)–Mas axis emerges as a novel therapeutic target in the context of cardiovascular -
Global Equity Fund Description Plan 3S DCP & JRA MICROSOFT CORP
Global Equity Fund June 30, 2020 Note: Numbers may not always add up due to rounding. % Invested For Each Plan Description Plan 3s DCP & JRA MICROSOFT CORP 2.5289% 2.5289% APPLE INC 2.4756% 2.4756% AMAZON COM INC 1.9411% 1.9411% FACEBOOK CLASS A INC 0.9048% 0.9048% ALPHABET INC CLASS A 0.7033% 0.7033% ALPHABET INC CLASS C 0.6978% 0.6978% ALIBABA GROUP HOLDING ADR REPRESEN 0.6724% 0.6724% JOHNSON & JOHNSON 0.6151% 0.6151% TENCENT HOLDINGS LTD 0.6124% 0.6124% BERKSHIRE HATHAWAY INC CLASS B 0.5765% 0.5765% NESTLE SA 0.5428% 0.5428% VISA INC CLASS A 0.5408% 0.5408% PROCTER & GAMBLE 0.4838% 0.4838% JPMORGAN CHASE & CO 0.4730% 0.4730% UNITEDHEALTH GROUP INC 0.4619% 0.4619% ISHARES RUSSELL 3000 ETF 0.4525% 0.4525% HOME DEPOT INC 0.4463% 0.4463% TAIWAN SEMICONDUCTOR MANUFACTURING 0.4337% 0.4337% MASTERCARD INC CLASS A 0.4325% 0.4325% INTEL CORPORATION CORP 0.4207% 0.4207% SHORT-TERM INVESTMENT FUND 0.4158% 0.4158% ROCHE HOLDING PAR AG 0.4017% 0.4017% VERIZON COMMUNICATIONS INC 0.3792% 0.3792% NVIDIA CORP 0.3721% 0.3721% AT&T INC 0.3583% 0.3583% SAMSUNG ELECTRONICS LTD 0.3483% 0.3483% ADOBE INC 0.3473% 0.3473% PAYPAL HOLDINGS INC 0.3395% 0.3395% WALT DISNEY 0.3342% 0.3342% CISCO SYSTEMS INC 0.3283% 0.3283% MERCK & CO INC 0.3242% 0.3242% NETFLIX INC 0.3213% 0.3213% EXXON MOBIL CORP 0.3138% 0.3138% NOVARTIS AG 0.3084% 0.3084% BANK OF AMERICA CORP 0.3046% 0.3046% PEPSICO INC 0.3036% 0.3036% PFIZER INC 0.3020% 0.3020% COMCAST CORP CLASS A 0.2929% 0.2929% COCA-COLA 0.2872% 0.2872% ABBVIE INC 0.2870% 0.2870% CHEVRON CORP 0.2767% 0.2767% WALMART INC 0.2767% -
The Evolution of Heart Failure with Reduced Ejection Fraction Pharmacotherapy: What Do We Have and Where Are We Going?
Pharmacology & Therapeutics 178 (2017) 67–82 Contents lists available at ScienceDirect Pharmacology & Therapeutics journal homepage: www.elsevier.com/locate/pharmthera Associate editor: M. Curtis The evolution of heart failure with reduced ejection fraction pharmacotherapy: What do we have and where are we going? Ahmed Selim, Ronald Zolty, Yiannis S. Chatzizisis ⁎ Division of Cardiovascular Medicine, University of Nebraska Medical Center, Omaha, NE, USA article info abstract Available online 21 March 2017 Cardiovascular diseases represent a leading cause of mortality and increased healthcare expenditure worldwide. Heart failure, which simply describes an inability of the heart to meet the body's needs, is the end point for many Keywords: other cardiovascular conditions. The last three decades have witnessed significant efforts aiming at the discovery Heart failure of treatments to improve the survival and quality of life of patients with heart failure; many were successful, Reduced ejection fraction while others failed. Given that most of the successes in treating heart failure were achieved in patients with re- Pharmacotherapy duced left ventricular ejection fraction (HFrEF), we constructed this review to look at the recent evolution of Novel drugs HFrEF pharmacotherapy. We also explore some of the ongoing clinical trials for new drugs, and investigate poten- tial treatment targets and pathways that might play a role in treating HFrEF in the future. © 2017 Elsevier Inc. All rights reserved. Contents 1. Introduction.............................................. -
Expression of POMC, Detection of Precursor Proteases, and Evidence
ORIGINAL ARTICLE See related commentary on page 1934 Human Mast Cells in the Neurohormonal Network: Expression of POMC, Detection of Precursor Proteases, and Evidence for IgE-Dependent Secretion of a-MSH Metin Artuc1, Markus Bo¨hm2, Andreas Gru¨tzkau1, Alina Smorodchenko1, Torsten Zuberbier1, Thomas Luger2 and Beate M. Henz1 Human mast cells have been shown to release histamine in response to the neuropeptide a-melanocyte- stimulating hormone (a-MSH), but it is unknown whether these cells express proopiomelanocortin (POMC) or POMC-derived peptides. We therefore examined highly purified human skin mast cells and a leukemic mast cell line-1 (HMC-1) for their ability to express POMC and members of the prohormone convertase (PC) family known to process POMC. Furthermore, we investigated whether these cells store and secrete a-MSH. Reverse transcriptase-PCR (RT-PCR) analysis revealed that both skin mast cells and HMC-1 cells express POMC mRNA and protein. Expression of the POMC gene at the RNA level in HMC-1 cells could be confirmed by Northern blotting. Transcripts for both PC1 and furin convertase were detectable in skin-derived mast cells and HMC-1 cells, as shown by RT-PCR. In contrast, PC2 transcripts were detected only in skin mast cells, whereas transcripts for paired basic amino acid converting enzyme 4 (PACE4) were present only in HMC-1 cells. Radio- immunoassays performed on cell lysates and cell culture supernatants from human skin-derived mast cells disclosed immunoreactive amounts of a-MSH in both fractions. Stimulation with an anti-IgE antibody significantly reduced intracellular a-MSH and increased extracellular levels, indicating IgE-mediated secretion of this neuropeptide. -
Selection and Characterization of Amyloid-Β1-42 Binding D-Enantiomeric Peptides for Potential Therapeutic Intervention of Alzheimer´S Disease
Selection and characterization of Amyloid-β1-42 binding D-enantiomeric peptides for potential therapeutic intervention of Alzheimer´s disease Inaugural-Dissertation zur Erlangung des Doktorgrades der Mathematisch-Naturwissenschaftlichen Fakultät der Heinrich-Heine-Universität Düsseldorf vorgelegt von Stephan Rudolph aus Dessau Düsseldorf, April 2015 Die vorliegende Arbeit wurde in der Zeit von April 2011 bis Februar 2015 am Institut für Physikalische Biologie der Heinrich-Heine-Universität Düsseldorf unter der Leitung von Prof. Dr. Dieter Willbold angefertigt. Gedruckt mit der Genehmigung der Mathematisch-Naturwissenschaftlichen Fakultät der Heinrich-Heine-Universität Düsseldorf Referent: Prof. Dr. Dieter Willbold Koreferent: Prof. Dr. Georg Groth Tag der mündlichen Prüfung: „Die Dummheiten wechseln, und die Dummheit bleibt.“ (Erich Kästner) „Die dunkelste Stunde ist die vor Sonnenaufgang.“ (chinesisches Sprichwort) Für Tante Elli Index Index Index I - IV 1. Introduction 1 1.1 Alzheimer´s disease (AD) – an overview .................................................... 1 1.1.1 General information ............................................................................. 1 1.1.2 History and pathology of AD ................................................................ 3 1.1.3 The amyloid precursor protein (APP) ................................................... 4 1.1.4 From APP to Aβ ................................................................................... 7 1.1.5 The physiological role of Aβ and Tau ................................................. -
Q4 2018 CDMO – Transaction Comps
Q4 2018 CDMO – Transaction Comps CDMO Transaction Comps USD in millions Announced Geographic Enterprise EV / LTM EV / LTM Date Target Target Description Buyer Location Value LTM Revenue LTM EBITDA Revenue EBITDA CDMO offering services including analytical testing, API and Nov-18 Avista Pharma Solutions1 Drug Product development, early stage discovery, and Cambrex Corporation USA $252.0 $65.0 NA 3.9x NA microbiology testing support Operates as a custom manufacturer of APIs and registered Jul-18 AMPAC Fine Chemicals LLC2 SK Holdings Co., Ltd. USA 455.0 200.0 NA NA NA intermediates for the pharmaceutical industry globally Provides contract development and manufacturing services in Jul-18 Halo Pharma, Inc. Cambrex Corporation USA 425.0 105.0 $27.0 4.0x 15.7x various dosage forms and drug delivery platforms Offers services in the areas of early-phase formulation Madison Dearborn Jun-18 Alcami Corporation USA NA NA NA NA NA development, analytical testing, and manufacturing Partners Provides contract development and manufacturing services to Catalent Pharma Sep-17 Cook Pharmica LLC USA 950.0 177.8 NA 5.3x NA pharmaceutical and biopharmaceutical companies Solutions, Inc. Provides drug discovery and development services as well as Jul-17 Aptuit LLC Evotec AG USA 300.0 92.9 11.6 3.2x 25.8x API development and manufacturing services Provides chemical and analytical development and custom Jun-17 PCAS SA Novacap France 335.9 243.7 19.7 1.4x 17.0x manufacturing services Contract research and manufacturing company that provides Jun-17 Albany Molecular Research, Inc. The Carlyle Group L.P.